Clinical trial
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
NCT00351000 · North Suffolk Mental Health Association, Other · Completed
Key facts
| NCT number | NCT00351000 |
|---|---|
| Title | Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus |
| Official title | An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia |
| Lead sponsor | North Suffolk Mental Health Association, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Ziprasidone |
| Enrollment | 24 |
| Start date | Jan 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Jul 12, 2006 |
| Last update posted | Jan 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: